ImmunityBio Inc
Company Profile
Business description
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Contact
3530 John Hopkins Court
San DiegoCA92121
USAT: +1 844 696-5235
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
673
Stocks News & Analysis
stocks
Amazon earnings: Guidance for $200 billion in capital expenditure in 2026 overshadows good results
stocks
Apple earnings: Impressive Q4 lifts stock, but is it a long-term growth play?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.10 | 65.20 | 0.72% |
| CAC 40 | 8,270.40 | 3.44 | -0.04% |
| DAX 40 | 24,776.03 | 54.57 | 0.22% |
| Dow JONES (US) | 50,115.67 | 1,206.95 | 2.47% |
| FTSE 100 | 10,358.05 | 11.70 | -0.11% |
| HKSE | 27,027.16 | 467.21 | 1.76% |
| NASDAQ | 23,031.21 | 490.63 | 2.18% |
| Nikkei 225 | 56,363.94 | 2,110.26 | 3.89% |
| NZX 50 Index | 13,446.37 | 2.35 | 0.02% |
| S&P 500 | 6,932.30 | 133.90 | 1.97% |
| S&P/ASX 200 | 8,870.10 | 59.20 | 0.67% |
| SSE Composite Index | 4,123.09 | 57.51 | 1.41% |